INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
25.11.25 | 15:29
1,650 Euro
+1,85 % +0,030
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,700 | 2,000 | 23:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.11. | Innate Pharma SA: Innate Pharma to Present at Jefferies Global Healthcare Conference | 239 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of... ► Artikel lesen | |
| 13.11. | Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances | 1 | Investing.com | ||
| 13.11. | Innate Pharma reports 9M results | 1 | Seeking Alpha | ||
| 13.11. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 13.11. | Innate Pharma SA: Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results | 284 | Business Wire | Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502... ► Artikel lesen | |
| 10.11. | Innate Pharma: Aktie legt nach grünem Licht der FDA für Phase-3-Studie kräftig zu | 13 | Investing.com Deutsch | ||
| 10.11. | Innate Pharma SA: Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL | 344 | Business Wire | The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line... ► Artikel lesen | |
| 05.11. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates | 258 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Thursday, November 13, 2025, at... ► Artikel lesen | |
| 23.10. | Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating | 2 | Investing.com | ||
| 15.10. | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.10. | Innate Pharma SA: Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 | 351 | Business Wire | The event will provide clinical perspectives and market outlook for lacutamab, Innate's lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase... ► Artikel lesen | |
| 18.09. | Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy | 4 | Investing.com | ||
| 18.09. | Innate Pharma: Leerink Partners stuft Aktie nach strategischem Schwenk herab | 4 | Investing.com Deutsch | ||
| 17.09. | Innate Pharma S.A. GAAP EPS of -€0.25, revenue of €4.9M | 4 | Seeking Alpha | ||
| 17.09. | Innate Pharma: Strategische Neuausrichtung auf Kernprojekte verlängert Liquiditätsreichweite bis Q3 2026 | 2 | Investing.com Deutsch | ||
| 17.09. | Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway | 1 | Investing.com | ||
| 17.09. | Earnings Call zu Q2 2025: Innate Pharma legt Fokus auf strategische Kern-Assets | 3 | Investing.com Deutsch | ||
| 17.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 17.09. | Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops | 1 | RTTNews |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,524 | +2,12 % | HV-Termine: Hauptversammlungen bei BVB, Brockhaus Technologies, CureVac, DISO Verwaltungs AG, Pearl Gold, SDM, The Grounds | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,598 | +2,30 % | Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 | Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025
Halle
To join the conference call via phone, participants may pre-register and will... ► Artikel lesen | |
| XOMA ROYALTY | 27,400 | -0,72 % | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. | EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| TME PHARMA | 0,062 | -0,48 % | TME Pharma announces receipt of agreements in principle to extend certain bond agreements | TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage... ► Artikel lesen | |
| CANSINO BIOLOGICS | 4,488 | -0,88 % | CanSino Biologics Inc: Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle | HONG KONG, Aug 20, 2025 - (ACN Newswire) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades... ► Artikel lesen | |
| KARYOPHARM | 4,720 | -2,88 % | Karyopharm Therapeutics Inc.: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies... ► Artikel lesen | |
| MEREO BIOPHARMA | 1,570 | +1,29 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
| ADICET BIO | 0,555 | +3,93 % | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 11,500 | -0,86 % | Citizens reiterates Market Outperform rating on Kalvista stock at $28 target | ||
| ANNOVIS BIO | 4,085 | +14,91 % | FDA schedules meeting with Annovis Bio on Parkinson's disease dementia | ||
| INTEGRA LIFESCIENCES | 10,300 | -5,50 % | Integra LifeSciences Holdings Corporation: Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access | ||
| NEUPHORIA THERAPEUTICS | 4,560 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Therapeutics Inc. Sends Letter to Stockholders | Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote "FOR" BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025... ► Artikel lesen | |
| RHYTHM PHARMACEUTICALS | 89,50 | +3,47 % | Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential | ||
| RECCE PHARMACEUTICALS | 0,212 | 0,00 % | Recce soft launches to combat search fatigue |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,85 % bei einem Aktienkurs von 1,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.